Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. news covered the company's shift from AI-driven oncology drug discovery into digital asset treasury and AI compute infrastructure activities. Recurring updates included financial results, Nasdaq listing compliance, a reverse stock split, private placements, governance changes, and the Aethir (ATH) token strategy tied to a Strategic Compute Reserve.
The company's oncology-related updates centered on its artificial intelligence and machine-learning platform, tumor sample biorepository, CLIA laboratory capabilities, and collaborations for drug repurposing and cancer therapy response prediction.
Predictive Oncology Inc. (NASDAQ: POAI) announced the successful closure of a transaction leading to gross cash proceeds of approximately $2.2 million from warrant exercises. The transaction involved the exercise of 1,396,826 shares at $1.575 per share, offering new unregistered warrants at $1.80 per share valid for five and a half years. The funds will be utilized for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The new warrants and shares will not be registered under the Securities Act, available only to accredited investors.
Predictive Oncology (NASDAQ: POAI) has made significant strides by fulfilling its first commercial order for specialized ovarian cancer cell culture media. This media, developed by its TumorGenesis division, allows researchers to grow patient-derived ovarian cancer cells more effectively, preserving crucial DNA, RNA, and proteomic signatures. The order was placed by a leading medical institution in New England. This innovative product aims to address the challenges posed by unvalidated media that increases research costs and reproducibility issues, ultimately driving advancements in cancer treatment research.
Predictive Oncology (NASDAQ: POAI) reported Q1 2020 revenues of $295,943, up from $255,241 year-over-year, driven primarily by STREAMWAY unit sales. Gross margins remained strong at 69%. However, net loss increased to $4.5 million from $3.3 million in the same quarter last year. The company is actively pursuing potential acquisitions to bolster its capabilities, including a COVID-19 vaccine development. The operational focus remains on the Helomics and TumorGenesis divisions, emphasizing AI applications in precision medicine.
Predictive Oncology (NASDAQ: POAI) has acquired the assets of Soluble Therapeutics and BioDtech, both subsidiaries of InventaBioTech, for 125,000 shares of common stock, alongside waiving a $1.07 million promissory note. This acquisition enhances Predictive's capabilities in precision medicine and drug formulation. CEO Dr. Carl Schwartz highlighted that the Soluble assets improve service offerings to pharmaceutical and biotech industries, while BioDtech's test allows monitoring of endotoxins, optimizing treatment strategies. These moves aim to bolster revenue prospects and expand the company’s market presence.
Predictive Oncology (NASDAQ: POAI) announced a registered direct offering of 1,396,826 shares of common stock at $1.575 per share, raising approximately $2.2 million. The offering includes unregistered warrants for the same number of shares, exercisable at $1.45 each for five and a half years. The company plans to use $487,000 of the net proceeds to repay debt and the remainder for working capital. The offering is expected to close on May 8, 2020, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.